NuCana (NASDAQ:NCNA) Announces Quarterly Earnings Results

NuCana (NASDAQ:NCNA) issued its quarterly earnings data on Thursday. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($2.43) by $2.11, Zacks reports.

NuCana Trading Down 1.2 %

NCNA traded down $0.01 during trading on Friday, hitting $0.80. The company’s stock had a trading volume of 2,357 shares, compared to its average volume of 419,954. NuCana has a twelve month low of $0.75 and a twelve month high of $10.79. The business’s fifty day simple moving average is $0.97 and its 200 day simple moving average is $1.56. The firm has a market capitalization of $2.11 million, a price-to-earnings ratio of -0.08 and a beta of 0.89.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.